Perspectives in the Rapidly Evolving Treatment Landscape of Multiple Myeloma: Expert Review of New Data Presentations from ASH 2019
Chng Wee Joo, Hang Quach, Noopur Raje
Clinical Lymphoma Myeloma & Leukemia | CIG MEDIA GROUP, LP | Published : 2020
The number and type of therapeutic options available to treat patients with multiple myeloma has risen dramatically over recent years, offering exciting opportunities to significantly improve the future management of this currently incurable disease. Some of the latest advances in the settings of newly diagnosed and relapsed/refractory multiple myeloma were presented at the 61st Annual Meeting of the American Society of Hematology (Orlando, Florida, December 7 to 10, 2019) and are reviewed in this article with accompanying expert commentary. Presentations covered the use of registry-generated real-world data to define the characteristics of 'functional' high-risk patients in order to enable ..View full abstract
This work was supported by Amgen Asia Holding Ltd. Chng Wee Joo has received grants from Amgen, Janssen, Celgene, and AbbVie, and honoraria from Amgen, Janssen, Celgene, AbbVie, and Takeda. Hang Quach has received research grants from Amgen, Celgene, Karyopharm, and GlaxoSmithKline; research drug supplies from Sanofi; and is an advisory board member for Amgen, Celgene, Karyopharm, GlaxoSmithKline, Janssen Cilag, and Specialized Therapeutics. Noopur Raje has received research funding from Bluebird Bio and AstraZeneca; is a consultant for Amgen, Bristol Myers Squibb, Celgene, Takeda, Karyopharm, and Janssen; and is on the Board of Directors of Caribou Biosciences.